What are Royalty Pharma's total assets?

Royalty Pharma (RPRX) holds $19.8B in total assets, up 12.5% year over year.

How much debt does Royalty Pharma have?

Royalty Pharma carries $9.0B in total debt against $9.9B of shareholders' equity, a debt-to-equity ratio of 0.90.

How much cash does Royalty Pharma have?

Royalty Pharma holds $586.4M in cash and equivalents.

Can Royalty Pharma cover its short-term obligations?

Its current ratio is 2.66 — current assets exceed current liabilities.

Where does Royalty Pharma's balance sheet data come from?

Every line is extracted from Royalty Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Royalty Pharma RPRX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$618.7M-33.4%	$929.03M+94.8%	$477.01M-72.1%	$1.71B+11.0%
Short-term investments	$18.8M-67.7%	$58.2M+218%	$18.3M+1,308%	$1.3M-98.0%
Accounts receivable, net	$20.46B+2,511%	$783.77M+6.1%	$738.44M+6.8%	$691.32M+12.5%
Prepaid expenses and other current assets	$6.89M+64.6%	$4.19M-76.8%	$18.04M-80.1%	$90.52M+1,265%
Total current assets	$1.53B-15.2%	$1.8B+41.4%	$1.27B-50.1%	$2.55B-11.2%
Goodwill	$924.63M—	$0—	——	——
Other non-current assets	$16.21B+7.1%	$15.13B+7.4%	$14.09B+4.4%	$13.49B-1.6%
Equity method investments	$289.97M-23.6%	$379.42M+0.9%	$375.89M-5.4%	$397.18M-8.8%
Available-for-sale securities	$419M-39.6%	$693.5M+58.7%	$437.1M+93.2%	$226.3M+10.7%
Total investments	$171.31M-8.4%	$186.96M-6.3%	$199.49M+77.6%	$112.35M-58.4%
Gross loans	$17.06B+7.2%	$15.91B+7.3%	$14.83B+4.5%	$14.18B-1.0%
Total assets	$19.62B+7.7%	$18.22B+11.2%	$16.38B-2.6%	$16.81B-4.0%
Accounts payable	$19.4M+45.1%	$13.37M-11.8%	$15.17M+91.8%	$7.91M+40.7%
Accrued expenses	$53.16M-22.5%	$68.6M+503%	$11.38M-8.3%	$12.4M—
Current portion of long-term debt	$380M-61.9%	$997.77M—	$0-100%	$997.51M—
Operating lease liabilities, current	$19.26M—	——	——	——
Accrued interest	$110.82M+13.0%	$98.06M+89.7%	$51.68M-4.6%	$54.16M-6.1%
Total current liabilities	$636.21M-49.2%	$1.25B+677%	$161.38M-86.2%	$1.17B+581%
Long-term debt	$8.57B+29.6%	$6.61B+7.8%	$6.14B+0.3%	$6.12B-13.8%
Operating Lease Liabilities (Total)	$19.26M—	——	——	——
Other non-current liabilities	$120.84M+900%	$12.08M+1,242%	$900K-64.0%	$2.5M—
Total liabilities	$9.91B+25.7%	$7.88B+25.1%	$6.3B-13.6%	$7.29B+0.3%
Additional paid-in capital	$4.12B+0.5%	$4.1B+2.3%	$4.01B+9.4%	$3.67B+4.5%
Retained earnings	$2.36B-17.2%	$2.85B+13.0%	$2.52B+28.1%	$1.96B-12.9%
Treasury stock	$2.61M-1.9%	$2.66M+1.3%	$2.63M-6.3%	$2.81M+3.4%
Noncontrolling interests	$3.24B-4.6%	$3.4B-4.6%	$3.56B-8.7%	$3.9B-12.9%
Total stockholders' equity	$9.71B-6.1%	$10.34B+2.6%	$10.08B+5.9%	$9.53B-7.1%
Total liabilities and stockholders' equity	$19.62B+7.7%	$18.22B+11.2%	$16.38B-2.6%	$16.81B-4.0%
Allowance for Credit Losses - Receivable (Current)	$3.4B-10.3%	$3.79B+23.6%	$3.07B+18.3%	$2.59B+52.9%
Available For Sale Securities Debt Securities Current	$18.8M-67.7%	$58.2M+218%	$18.3M+1,308%	$1.3M-98.0%
Other current assets	$6.89M+64.6%	$4.19M-76.8%	$18.04M-80.1%	$90.52M+1,265%
Other royalty income receivable	$29.32M+8.8%	$26.96M+20.3%	$22.41M+13.3%	$19.77M+31.6%
Equipment Installment Plan Receivables, Gross	$20.46B+3.9%	$19.7B+10.1%	$17.89B+6.7%	$16.78B+4.7%
Finance Receivables (Current)	$854.39M+9.0%	$783.77M+6.1%	$738.44M+6.8%	$691.32M+12.5%
Financing Receivables	$17.06B+7.2%	$15.91B+7.3%	$14.83B+4.5%	$14.18B-1.0%
Loans and Lending Commitments	$17.06B+7.2%	$15.91B+7.3%	$14.83B+4.5%	$14.18B-1.0%
Purchased Credit Deteriorated Loans	$17.06B+7.2%	$15.91B+7.3%	$14.83B+4.5%	$14.18B-1.0%
Deferred Tax Assets and Other Non-Current Assets	$79.29M+136%	$33.53M+414%	$6.52M-78.0%	$29.63M+615%
Equipment Installment Plan Receivables (Non-Current), Net	$16.21B+7.1%	$15.13B+7.4%	$14.09B+4.4%	$13.49B-1.6%
Equity Securities (FV-NI) - Non-Current	$171.31M-8.4%	$186.96M-6.3%	$199.49M+77.6%	$112.35M-58.4%
Equity Securities (Non-Current)	$171.31M-8.4%	$186.96M-6.3%	$199.49M+77.6%	$112.35M-58.4%
Long-term marketable securities	$419M-39.6%	$693.5M+58.7%	$437.1M+93.2%	$226.3M+10.7%
Long-term financing receivables (net of allowances of $27 in 2026 and $34 in 2025)	$16.21B+7.1%	$15.13B+7.4%	$14.09B+4.4%	$13.49B-1.6%
Other non-current assets	$79.29M+136%	$33.53M+414%	$6.52M-78.0%	$29.63M+615%
Software and Technology Licenses, Net	$79.29M+136%	$33.53M+414%	$6.52M-78.0%	$29.63M+615%
Accounts payable and other current liabilities (Note 11)	$19.4M+45.1%	$13.37M-11.8%	$15.17M+91.8%	$7.91M+40.7%
Distributions payable to non-controlling interests	$72.83M-3.9%	$75.81M—	——	——
Other accrued liabilities	$53.16M-22.5%	$68.6M+503%	$11.38M-8.3%	$12.4M—
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——
Lease Liability Payments - Due Year Three	——	——	——	——
Lease Liability Payments - Due Year Four	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——
Operating Lease Liability Payments Due	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——	——
Debt - Unamortized Discount (Premium) and Issuance Costs, Net	$229.08M+22.1%	$187.57M+13.9%	$164.72M-10.3%	$183.68M-9.9%
Operating Lease Liability Payments - 2026 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	——	——	——	——
Deferred shares, $0.000001 par value; issued and outstanding: 2026–427,355 and 2025–411,475	$0—	$0—	$0—	$0—
Share Price	——	——	——	——
Share Repurchase Authorization Limit	——	——	——	——
Share Repurchase Program - Amount Remaining	——	——	——	——
Nonperforming Loans and Leases Percentage	$20.46B+3.9%	$19.7B+10.1%	$17.89B+6.7%	$16.78B+4.7%
Accrued liabilities	$577.87M—	$0—	——	——
Quarterly conversion basis (in shares)	——	——	——	——
Number of votes per share	——	——	——	——
Less: net unamortized discount	$229.08M+22.1%	$187.57M+13.9%	$164.72M-10.3%	$183.68M-9.9%
Deferred stock, par value (in dollars per share)	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Deferred stock, issued (in shares)	411.5M+4.9%	392.3M+2.0%	384.6M+3.6%	371.3M+2.8%
Deferred stock, outstanding (in shares)	411.5M+4.9%	392.3M+2.0%	384.6M+3.6%	371.3M+2.8%
Equity method investments (Note 11)	$289.97M-23.6%	$379.42M+0.9%	$375.89M-5.4%	$397.18M-8.8%
Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows	$3.19B-10.3%	$3.55B+21.3%	$2.93B+18.2%	$2.48B+78.9%
Financing Receivable, Allowance For Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)	$211.96M-11.0%	$238.12M+72.9%	$137.71M+19.3%	$115.42M-62.9%
Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows	$17.27B+7.0%	$16.15B+7.9%	$14.96B+4.7%	$14.3B-2.3%
Lessee Operating Lease Liability Payments Due	——	——	——	——
Thereafter	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——	——
Noncontrolling interests in subsidiaries	$3.24B-4.6%	$3.4B-4.6%	$3.56B-8.7%	$3.9B-12.9%
Number of classes of stock	——	——	——	——
Number of noncontrolling interests created	——	——	——	——
Total Commitments	——	——	——	——
Unfunded Commitments	——	——	——	——
Share price (in dollars per share)	——	——	——	——
Share Repurchase Program, Authorized, Amount	——	——	——	——
Share Repurchase Program, Remaining Authorized, Amount	——	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Royalty Pharma.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Royalty Pharma's total assets?: Royalty Pharma (RPRX) holds $19.8B in total assets, up 12.5% year over year.
How much debt does Royalty Pharma have?: Royalty Pharma carries $9.0B in total debt against $9.9B of shareholders' equity, a debt-to-equity ratio of 0.90.
How much cash does Royalty Pharma have?: Royalty Pharma holds $586.4M in cash and equivalents.
Can Royalty Pharma cover its short-term obligations?: Its current ratio is 2.66 — current assets exceed current liabilities.
Where does Royalty Pharma's balance sheet data come from?: Every line is extracted from Royalty Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.